STATE OF THE ART PAPER
Cardiotoxicity of anthracycline therapy: current perspectives
 
More details
Hide details
Submission date: 2014-08-01
Final revision date: 2014-09-17
Acceptance date: 2014-10-07
Online publication date: 2016-04-12
Publication date: 2016-04-11
 
Arch Med Sci 2016;12(2):428–435
 
KEYWORDS
TOPICS
ABSTRACT
Anthracyclines, especially doxorubicin and daunorubicin, are the drugs of first choice in the treatment of patients with hematologic malignancies, soft-tissue sarcomas, and solid tumors. Unfortunately, the use of anthracyclines is limited by their dose-dependent and cumulative cardiotoxicity. The molecular mechanism responsible for anthracycline-induced cardiotoxicity remains poorly understood, although experimental and clinical studies have shown that oxidative stress plays the main role. Hence, antioxidant agents, especially dexrazoxane, and also other drug classes (statins, -blockers) proved to have a beneficial effect in protecting against anthracycline-induced cardiotoxicity. According to previous clinical trials, the major high-risk factors for anthracycline-induced cardiotoxicity are age, body weight, female gender, radiotherapy, and other diseases such as Down syndrome, familial dilated cardiomyopathy, diabetes and hypertension. Consequently, further studies are needed to elucidate the molecular pathogenesis of anthracycline-induced cardiotoxicity and also to discover new cardioprotective agents against anthracycline-induced cardiotoxicity.
eISSN:1896-9151
ISSN:1734-1922